JP5188988B2 - ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 - Google Patents

ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 Download PDF

Info

Publication number
JP5188988B2
JP5188988B2 JP2008554398A JP2008554398A JP5188988B2 JP 5188988 B2 JP5188988 B2 JP 5188988B2 JP 2008554398 A JP2008554398 A JP 2008554398A JP 2008554398 A JP2008554398 A JP 2008554398A JP 5188988 B2 JP5188988 B2 JP 5188988B2
Authority
JP
Japan
Prior art keywords
indazol
carboxylic acid
amide
benzimidazol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008554398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526072A5 (OSRAM
JP2009526072A (ja
Inventor
エム．エム． ムジャリ，アドナン
エス． グレラ，ブライアン
サブラマニアン，ゴビンダン
エヌ． アリミリ，マーティー
ゴパラスワミー，ラメシュ
シー． アンドリュース，ロバート
デイビス，スティーブン
クオ，シャオチャン
チュウ，ジェフ
Original Assignee
トランステック ファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランステック ファーマ，インコーポレイティド filed Critical トランステック ファーマ，インコーポレイティド
Publication of JP2009526072A publication Critical patent/JP2009526072A/ja
Publication of JP2009526072A5 publication Critical patent/JP2009526072A5/ja
Application granted granted Critical
Publication of JP5188988B2 publication Critical patent/JP5188988B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2008554398A 2006-02-10 2007-02-09 ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 Expired - Fee Related JP5188988B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77249706P 2006-02-10 2006-02-10
US60/772,497 2006-02-10
US79118706P 2006-04-11 2006-04-11
US60/791,187 2006-04-11
PCT/US2007/003579 WO2007095124A2 (en) 2006-02-10 2007-02-09 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2009526072A JP2009526072A (ja) 2009-07-16
JP2009526072A5 JP2009526072A5 (OSRAM) 2011-07-07
JP5188988B2 true JP5188988B2 (ja) 2013-04-24

Family

ID=38157823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008554398A Expired - Fee Related JP5188988B2 (ja) 2006-02-10 2007-02-09 ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法

Country Status (9)

Country Link
US (2) US7820821B2 (OSRAM)
EP (2) EP1987028A2 (OSRAM)
JP (1) JP5188988B2 (OSRAM)
CN (2) CN101379060B (OSRAM)
AU (1) AU2007215247B2 (OSRAM)
BR (1) BRPI0708034A2 (OSRAM)
CA (1) CA2641744C (OSRAM)
IL (1) IL192580A0 (OSRAM)
WO (1) WO2007095124A2 (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608581A2 (pt) * 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
HUE031972T2 (en) 2005-12-29 2017-08-28 Celtaxsys Inc Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2009064835A1 (en) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009084008A1 (en) * 2007-12-28 2009-07-09 Cadila Healthcare Limited Process for preparing mycophenolate mofetil
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
WO2010036613A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
AU2010259035A1 (en) 2009-06-08 2011-12-08 Gilead Sciences, Inc. Alkanoylamino benzamide aniline HDAC inhibitor compounds
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
US9125901B2 (en) 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
SG182629A1 (en) 2010-02-18 2012-08-30 High Point Pharmaceuticals Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8586604B2 (en) * 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) * 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
WO2014008477A2 (en) 2012-07-06 2014-01-09 Duke University Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch
WO2014100158A1 (en) 2012-12-18 2014-06-26 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
ES2677115T3 (es) 2013-03-12 2018-07-30 Vertex Pharmaceuticals Incorporated Derivados de manosa para tratar las infecciones bacterianas
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
KR20150131211A (ko) 2013-03-14 2015-11-24 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
WO2014193696A2 (en) 2013-05-28 2014-12-04 Transtech Pharma, Llc Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
US20170152263A1 (en) * 2014-06-20 2017-06-01 Aurigene Discovery Technologies Limited Substituted Indazole Compounds as IRAK4 Inhibitors
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
CN114907271B (zh) * 2015-05-22 2024-05-07 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
WO2016207785A1 (en) 2015-06-22 2016-12-29 Actelion Pharmaceuticals Ltd Nadph oxidase 4 inhibitors
CN109310683A (zh) 2016-04-07 2019-02-05 杜克大学 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
WO2018178947A2 (en) 2017-03-31 2018-10-04 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
MY203827A (en) 2017-10-31 2024-07-19 Curis Inc Compounds and compositions for treating hematological disorders
CA3093551A1 (en) * 2018-03-29 2019-10-03 Elex Biotech, Inc. Compounds for treatment of cardiac arrhythmias and heart failure
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
EP3952990A1 (en) * 2019-04-12 2022-02-16 Mitobridge, Inc. Hmox1 inducers
TW202116754A (zh) 2019-07-11 2021-05-01 美商Ｅ 斯蓋普生物股份有限公司 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑
BR112022010561A2 (pt) 2019-12-02 2022-11-16 Storm Therapeutics Ltd Compostos poli-heterocíclicos como inibidores de mettl3
CN110903246A (zh) * 2019-12-19 2020-03-24 赵洁 一种用于治疗甲状腺癌的化合物及其组合物和医药用途
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN112552287B (zh) * 2020-12-16 2021-11-30 北京华氏精恒医药科技有限公司 一种吲哚类衍生物药物制剂及其制备方法
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
AU2022254933A1 (en) 2021-04-08 2023-11-09 Curis, Inc. Combination therapies for the treatment of cancer
CN115594671B (zh) * 2021-07-08 2024-03-15 沈阳药科大学 苯并噻唑类衍生物及其制备方法和用途
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5481271A (en) 1977-12-09 1979-06-28 Ouchi Shinkou Kagaku Kougiyou Benzimidazole derivatives and manufacture
EP0178413A1 (en) * 1984-08-17 1986-04-23 Beecham Group Plc Benzimidazoles
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
SE8604566D0 (sv) 1986-10-27 1986-10-27 Haessle Ab Novel compunds
FR2643903A1 (fr) * 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US6288100B1 (en) 1995-06-06 2001-09-11 American Home Products Corporation Benzimidazole derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AU7001396A (en) 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2000143635A (ja) 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
JP4622020B2 (ja) * 1999-02-26 2011-02-02 住友電気工業株式会社 絶縁被膜を有する酸化物超電導線材およびその製造方法
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6326385B1 (en) * 1999-08-04 2001-12-04 Icagen, Inc. Methods for treating or preventing pain
ATE399753T1 (de) * 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU2001264872A1 (en) * 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
WO2002053160A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
AU2002232919A1 (en) * 2000-12-29 2002-07-16 Alteon, Inc. Method for treating fibrotic diseases or other indications
KR20030078958A (ko) * 2001-03-01 2003-10-08 시오노기세이야쿠가부시키가이샤 Ｈｉｖ 인테그라제 저해 활성을 갖는 질소 함유의헤테로아릴 화합물
US20030109714A1 (en) * 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
BR0215212A (pt) * 2001-12-21 2004-12-07 Novo Nordisk As Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
EP1475368A4 (en) * 2002-02-14 2006-03-29 Ono Pharmaceutical Co FUSED CORE COMPOUNDS CONTAINING N-CARBAMOYL NITROGEN AND MEDICAMENTS CONTAINING SAID COMPOUNDS AS ACTIVE INGREDIENTS
ATE353013T1 (de) * 2002-02-19 2007-02-15 Pfizer Italia Srl Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
DE10207037A1 (de) * 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
WO2003082265A2 (en) * 2002-04-02 2003-10-09 Fujisawa Pharmaceutical Co Pharmaceutical composition for treating or preventing virus infectious diseases
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
GB0311201D0 (en) * 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7560467B2 (en) * 2003-06-19 2009-07-14 Smithkline Beecham Corporation Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors
JP2007502298A (ja) 2003-08-14 2007-02-08 スミスクライン ビーチャム コーポレーション 化合物
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
ES2327418T3 (es) * 2003-10-16 2009-10-29 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf.
DE10349587A1 (de) * 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005090379A1 (en) 2004-03-17 2005-09-29 The Central Science Laboratory, 'csl' Compounds and sensor for detecion of polycyclic aromatic hydrocarbons
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
US20060068998A1 (en) * 2004-09-27 2006-03-30 Fuji Photo Film Co. Ltd. Lubricant composition and triazine ring-containing compound
ES2316053T3 (es) 2005-02-10 2009-04-01 Smithkline Beecham Corporation Compuestos de piridopirazolopirimidina y sus usos como farmacos contra el cancer y contra la diabetes.
BRPI0608581A2 (pt) 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
CN101448506A (zh) * 2005-12-02 2009-06-03 拜尔健康护理有限责任公司 通过抑制有丝分裂酶激酶治疗癌症的吡咯并三嗪衍生物

Also Published As

Publication number Publication date
CA2641744C (en) 2012-09-25
CA2641744A1 (en) 2007-08-23
CN101379060B (zh) 2012-05-23
AU2007215247A1 (en) 2007-08-23
US20100152170A1 (en) 2010-06-17
US7820821B2 (en) 2010-10-26
WO2007095124A3 (en) 2007-11-01
US20070219235A1 (en) 2007-09-20
US8377983B2 (en) 2013-02-19
CN101379060A (zh) 2009-03-04
AU2007215247B2 (en) 2012-12-13
CN102633783A (zh) 2012-08-15
HK1125631A1 (en) 2009-08-14
WO2007095124A2 (en) 2007-08-23
IL192580A0 (en) 2009-02-11
EP1987028A2 (en) 2008-11-05
EP2295432A1 (en) 2011-03-16
BRPI0708034A2 (pt) 2011-05-17
JP2009526072A (ja) 2009-07-16

Similar Documents

Publication Publication Date Title
JP5188988B2 (ja) ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法
JP6898868B2 (ja) Ｈｐｋ１阻害剤およびそれを用いる方法
JP2019048833A (ja) Ｆａｓｎを阻害するための新規化合物および組成物
JP2013515736A (ja) キナーゼ調節のための化合物及び方法ならびにそれらの適応症
JP2011510010A (ja) ３Ｈ−［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
US12090149B2 (en) SMAD3 inhibitors
JP2013082757A (ja) プロテインキナーゼ阻害薬として有用なベンズイミダゾール
CN102317288A (zh) 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
JP7477846B2 (ja) Ｎを含むヘテロアリール誘導体およびこれを有効成分として含むがんの予防または治療用薬学的組成物
CN107417687A (zh) 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
US20200024272A1 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
US20200055847A1 (en) Modulators of hedgehog (hh) signalling pathway
US10745360B2 (en) Quinoxaline compounds, method for preparing the same and use thereof
KR102329720B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
HK1125631B (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
MX2008009811A (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
HK1170723A (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
HK40057478A (en) Hpk1 inhibitors and methods of using same
US20250282794A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
KR20210048701A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
HK1255833B (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130123

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160201

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees